Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 16Esophageal Neoplasms 5Stomach Neoplasms 3Neoplasms 3Neoplasm Metastasis 3HER2-positive Breast Cancer 3Colorectal Neoplasms 3Adenocarcinoma Of Esophagus 3Triple Negative Breast Neoplasms 2Solid Tumors 2Rectal Neoplasms 2Prostatic Neoplasms 2Multiple Myeloma 2Endometrial Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Pathologic Complete Response 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm, Residual 1Meningeal Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma, Non-Hodgkin 1

Interventions

sapanisertib 1pertuzumab 1Trastuzumab 1Radiotherapy 1Methotrexate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningeal Neoplasms × Trastuzumab × 30 days × Clear all
NCT04588545 2026-05-26

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Active not recruiting
33 enrolled
CNS

Meningeal Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡